Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: Exploratory case-control study
BMJ Jun 28, 2018
Given JE, et al. - Using malformed controls, population based exploratory case-control study was conducted to examine whether exposure to metformin during the first trimester of pregnancy, for diabetes or other indications, increases the risk of all or specific congenital anomalies. Participants in the study were 50,167 babies affected by congenital anomaly including live births, fetal deaths from 20 weeks’ gestation, and terminations of pregnancy for fetal anomaly. Researchers did not find evidence for an increased risk of all non-genetic congenital anomalies combined following exposure to metformin during the first trimester. Outcomes suggested that a signal for an increased risk of pulmonary valve atresia could be a chance finding.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries